Find Zanubrutinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1691249-45-2, Brukinsa, Bgb-3111, Zanubrutinib [inn], Zanubrutinib [usan], Ag9mhg098z
Molecular Formula
C27H29N5O3
Molecular Weight
471.5  g/mol
InChI Key
RNOAOAWBMHREKO-QFIPXVFZSA-N
FDA UNII
AG9MHG098Z

Zanubrutinib
Zanubrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.
Zanubrutinib is a Kinase Inhibitor. The mechanism of action of zanubrutinib is as a Bruton's Tyrosine Kinase Inhibitor.
1 2D Structure

Zanubrutinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
2.1.2 InChI
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
2.1.3 InChI Key
RNOAOAWBMHREKO-QFIPXVFZSA-N
2.1.4 Canonical SMILES
C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
2.1.5 Isomeric SMILES
C=CC(=O)N1CCC(CC1)[C@@H]2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
2.2 Other Identifiers
2.2.1 UNII
AG9MHG098Z
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (7s)-2-(4-phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide

2. 7-(1-acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide

3. Bgb-3111

4. Brukinsa

2.3.2 Depositor-Supplied Synonyms

1. 1691249-45-2

2. Brukinsa

3. Bgb-3111

4. Zanubrutinib [inn]

5. Zanubrutinib [usan]

6. Ag9mhg098z

7. 1691249-45-2 (s-isomer)

8. (7s)-2-(4-phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide

9. Bgb3111

10. (7s)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide

11. (7s)-4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

12. (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide

13. Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7s)-

14. Brukinsa (tn)

15. Zanubrutinib [mi]

16. Zanubrutinib (usan/inn)

17. Zanubrutinib [usan:inn]

18. Unii-ag9mhg098z

19. Bgb-3111(zanubrutinib)

20. Zanubrutinib (bgb-3111)

21. Zanubrutinib [who-dd]

22. Gtpl9861

23. Chembl3936761

24. Schembl17842597

25. Bdbm250082

26. Dtxsid701026208

27. Zanubrutinib [orange Book]

28. Compound 27b [us9447106]

29. Bcp29110

30. Ex-a3602

31. Nsc823807

32. S8791

33. Zinc584641430

34. At18252

35. Db15035

36. Hy-101474a

37. Nsc-823807

38. Us9447106, 27b (peak 2)

39. Bs-15529

40. Bz168474

41. Cs-0021869

42. D11422

43. Bgb-3111; Bgb 3111; Bgb3111

44. A934931

45. 1651179-04-2

46. 7-(1-acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide

2.4 Create Date
2019-01-15
3 Chemical and Physical Properties
Molecular Weight 471.5 g/mol
Molecular Formula C27H29N5O3
XLogP33.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass471.22703980 g/mol
Monoisotopic Mass471.22703980 g/mol
Topological Polar Surface Area103 Ų
Heavy Atom Count35
Formal Charge0
Complexity756
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is used to treat Waldenstrms macroglobulinemia in adults. Zanubrutinib is also indicated for the treatment of relapsed or refractory marginal zone lymphoma (MZL) in adults who have received at least one anti-CD20-based regimen.


Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenstrms macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Zanubrutinib is an immunomodulating agent that decreases the survival of malignant B cells. It inhibits BTK by binding to its active site. It works to inhibit the proliferation and survival of malignant B cells to reduce the tumour size in mantle cell lymphoma.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Hematologic Agents

Drugs that act on blood and blood-forming organs and those that affect the hemostatic system. (See all compounds classified as Hematologic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
ZANUBRUTINIB
5.3.2 FDA UNII
AG9MHG098Z
5.3.3 Pharmacological Classes
Kinase Inhibitor [EPC]; Bruton's Tyrosine Kinase Inhibitors [MoA]
5.4 ATC Code

L01


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EL - Bruton's tyrosine kinase (btk) inhibitors

L01EL03 - Zanubrutinib


5.5 Absorption, Distribution and Excretion

Absorption

Following oral administration of zanubrutinib 160 mg twice daily and 320 mg once daily, the mean (%CV) zanubrutinib steady-state concentrations were 2,295 (37%) ngh/mL and 2,180 (41%) ngh/mL, respectively. The mean Cmax (%CV) was 314 (46%) ng/mL following 160 mg twice daily and 543 (51%) ng/mL following 320 mg once daily. The Cmax and AUC of zanubrutinib increase in a dose-proportional manner and there is minimal systemic accumulation after repeated dosing. The median Tmax is 2 hours.


Route of Elimination

Following oral administration of 320 mg radiolabelled zanubrutinib, approximately 87% of the dose was excreted in the feces and about 8% of the dose was recovered in the urine, where less than 1% of the recovered drug comprised of unchanged parent drug.


Volume of Distribution

The geometric mean (%CV) apparent steady-state Vd is 881 (95%) L. The blood-to plasma ratio is about 0.7 to 0.8.


Clearance

The mean (%CV) apparent oral clearance (CL/F) of zanubrutinib is 182 (37%) L/h.


5.6 Metabolism/Metabolites

Zanubrutinib is predominantly metabolized by CYP3A4. Its metabolites have not been characterized.


5.7 Biological Half-Life

Following administration of a single oral dose of 160 mg or 320 mg of zanubrutinib, the mean half-life is approximately 2 to 4 hours.


5.8 Mechanism of Action

Bruton's tyrosine kinase (BTK) is a non-receptor kinase and a signalling molecule for the B cell receptors expressed on the peripheral B cell surface. The BCR signalling pathway plays a crucial role in normal B-cell development but also the proliferation and survival of malignant B cells in many B cell malignancies, including mantle-cell lymphoma (MCL). Once activated by upstream Src-family kinases, BTK phosphorylates phospholipase-C (PLC), leading to Ca2+ mobilization and activation of NF-B and MAP kinase pathways. These downstream cascades promote the expression of genes involved in B cell proliferation and survival. The BCR signalling pathway also induces the anti-apoptotic protein Bcl-xL and regulates the integrin 41 (VLA-4)-mediated adhesion of B cells to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin via BTK. Apart from the direct downstream signal transduction pathway of B cells, BTK is also involved in chemokine receptor, Toll-like receptor (TLR) and Fc receptor signalling pathways. Zanubrutinib inhibits BTK by forming a covalent bond with cysteine 481 residue in the adenosine triphosphate (ATP)binding pocket of BTK, which is the enzyme's active site. This binding specificity is commonly seen with other BTK inhibitors. Due to this binding profile, zanubrutinib may also bind with varying affinities to related and unrelated ATP-binding kinases that possess a cysteine residue at this position. By blocking the BCR signalling pathway, zanubrutinib inhibits the proliferation, trafficking, chemotaxis, and adhesion of malignant B cells, ultimately leading to reduced tumour size. Zanubrutinib was also shown to downregulate programmed death-ligand 1 (PD-1) expression and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on CD4+ T cells.


API SUPPLIERS

read-more
read-more

01

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

02

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

03

Lee Fine Chem

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

04

Olon S.p.A

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

Olon S.p.A

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
CPhI India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

05

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
CPhI India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
CPhI India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

07

Beijing Sjar Technology Developmen...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

08

Medichem S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

09

Daishang Pharmchem Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

10

Synthimed Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India
Not Confirmed
arrow

Synthimed Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
CPhI India
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 54893-0502

Start Marketing Date : 2023-03-31

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 54893-0510

Start Marketing Date : 2024-03-27

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

Olon S.p.A.

Italy
COMPAMED
Not Confirmed
arrow

Olon S.p.A.

Italy
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 17337-0321

Start Marketing Date : 2023-03-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

Olon S.p.A.

Italy
COMPAMED
Not Confirmed
arrow

Olon S.p.A.

Italy
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 17337-0322

Start Marketing Date : 2023-03-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

Siegfried Evionnaz SA

Switzerland
COMPAMED
Not Confirmed
arrow

Siegfried Evionnaz SA

Switzerland
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 17381-929

Start Marketing Date : 2019-10-14

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

Siegfried AG

Switzerland
COMPAMED
Not Confirmed
arrow

Siegfried AG

Switzerland
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 17205-628

Start Marketing Date : 2023-06-16

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

07

COMPAMED
Not Confirmed
arrow
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 24538-311

Start Marketing Date : 2019-11-14

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

Esteve Quimica SA

Country
COMPAMED
Not Confirmed
arrow

Esteve Quimica SA

Country
arrow
COMPAMED
Not Confirmed

ZANUBRUTINIB

NDC Package Code : 57572-0729

Start Marketing Date : 2025-09-25

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Zanubrutinib

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Zanubrutinib

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.

Flag India
Digital Content Digital Content

Zanubrutinib

About the Company : Lee Fine Chem Private Limited specializes in Advanced Intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms. With a strong focus on quality and innovat...

Lee Fine Chem Private Limited specializes in Advanced Intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms. With a strong focus on quality and innovation, we deliver high-performance pharmaceutical solutions to global markets. Our state-of-the-art facilities and expert team ensure compliance, consistency, and excellence at every stage of development and production. Trust Lee Fine Chem for reliable, efficient, and cutting-edge pharmaceutical products.
Company Banner

04

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

Zanubrutinib

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank

05

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

Zanubrutinib

About the Company : Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, o...

Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, optimized management and robust service system for our customers. Daishang Chem is specialized in the researching, manufacturing, sales and marketing of API & Its Intermediates as well as other Fine Chemicals, taking great advantages of professional and proficient staff, based on three chemical manufacturing sites and one GMP manufacturing workshops in Liaoning, Henan and Zhejiang provinces, and one R&D laboratory in Zhangjiang Hi-tech Park.
blank

06

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

Zanubrutinib

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance. Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 1986.
blank

07

Medichem S.A

Spain
The Pharmacy Technology
Not Confirmed
arrow

Medichem S.A

Spain
arrow
The Pharmacy Technology
Not Confirmed

Zanubrutinib

About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...

Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Active Pharmaceutical Ingredients (APIs), including Highly Potent. In 2016, Medichem merged with Combino Pharm, which is devoted to the development and manufacture (licensing) of Finished Dosage Forms. With this merger, Medichem has become a vertically integrated pharmaceutical company which can offer a complete range of products and services for the pharmaceutical industry with the highest standards of quality, operational excellence and environment respect.
blank

08

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

Zanubrutinib

About the Company : Synthimed Labs is a leading API manufacturer recognized for its high-quality and diverse range of Active Pharmaceutical Ingredients (APIs). Their product portfolio includes a wide ...

Synthimed Labs is a leading API manufacturer recognized for its high-quality and diverse range of Active Pharmaceutical Ingredients (APIs). Their product portfolio includes a wide array of APIs developed through advanced research and rigorous quality control processes.
blank

09

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

Zanubrutinib

About the Company : Zydus is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states...

Zydus is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil. Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713983400,"product":"ZANUBRUTINIB (FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"HONG KONG","customer":"BIOBETTA PHARMACEUTICALS SHANGHAI C","customerCountry":"CHINA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"30000","totalValueFC":"59193","currency":"USD","unitRateINR":2471524,"date":"25-Apr-2024","totalValueINR":"4943048","totalValueInUsd":"59193","indian_port":"Hyderabad Air","hs_no":"29397900","bill_no":"9395507","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1730140200,"product":"ZANUBRUTINIB (FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"PARIS - CHARLES DE G","customer":"SANOFI AVENTIS RECHERCHE ETDEVELOPP","customerCountry":"FRANCE","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"100000","totalValueFC":"4901","currency":"USD","unitRateINR":4118160,"date":"29-Oct-2024","totalValueINR":"411816","totalValueInUsd":"4901","indian_port":"Hyderabad Air","hs_no":"29397900","bill_no":"5253555","productDescription":"API","marketType":"REGULATED MARKET","country":"FRANCE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1761589800,"product":"ZANUBRUTINIB","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"APIIC MAHABOOBNAGAR","customer":"HETERO LABS LTD SEZ UNIT I","customerCountry":"INDIA","quantity":"8.00","actualQuantity":"8","unit":"KGS","unitRateFc":"13669.6","totalValueFC":"107660.6","currency":"USD","unitRateINR":1189251.6112500001,"date":"28-Oct-2025","totalValueINR":"9514012.89","totalValueInUsd":"107660.6","indian_port":"SEZ\/Mahaboobnagar","hs_no":"29334900","bill_no":"6486840","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"SEZ\/Mahaboobnagar","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649615400,"product":"ZANUBRUTINIB [DRUG LICENCE NO:TL\/HZ\/20\/002419 DT:07.09.2020]","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"NA","customer":"NOVARTIS HEALTHCARE PRIVATE LTD","customerCountry":"INDIA","quantity":"0.60","actualQuantity":"0.6","unit":"KGS","unitRateFc":"35000","totalValueFC":"21376.1","currency":"USD","unitRateINR":"2688000","date":"11-Apr-2022","totalValueINR":"1612800","totalValueInUsd":"21376.1","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"8222440","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663180200,"product":"LUT-71 ZANUBRUTINIB (ZANUBRUTINIB AMORPHOUS MILLED ) (BATCHNO 22001PR87L AND 22002PR87L)","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"NA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"5.01","actualQuantity":"5.013","unit":"KGS","unitRateFc":"42000","totalValueFC":"211357.7","currency":"USD","unitRateINR":"3378900","date":"15-Sep-2022","totalValueINR":"16938425.7","totalValueInUsd":"211357.7","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"2450460","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671993000,"product":"LUT-71 ZANUBRUTINIB (ZANUBRUTINIB AMORPHOUS MILLED) BATCH NO 22004LR87L","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"NA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"11.43","actualQuantity":"11.425","unit":"KGS","unitRateFc":"47409","totalValueFC":"549165.5","currency":"USD","unitRateINR":"3961022","date":"26-Dec-2022","totalValueINR":"45254675.78","totalValueInUsd":"549165.5","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"3908851","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"ZANUBRUTINIB AMORPHOUS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN","customer":"HETERO LABS LTD","customerCountry":"INDIA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"25000","totalValueFC":"6310.1","currency":"USD","unitRateINR":"2130000","date":"12-Nov-2024","totalValueINR":"532500","totalValueInUsd":"6310.1","indian_port":"Madras Air","hs_no":"29335990","bill_no":"6634272","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN","supplierAddress":"STRADA RIVOLTANA KM 6\/7 RODANO MI 20053 SDNF ITALY","customerAddress":"HETERO CORPORATE, NO. 7-2-A2,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738780200,"product":"ZANUBRUTINIB AMORPHOUS ZANUBRUTINIB AMORPHOUS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN","customer":"HETERO LABS LTD","customerCountry":"INDIA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"25000","totalValueFC":"6259.8","currency":"USD","unitRateINR":"2177500","date":"06-Feb-2025","totalValueINR":"544375","totalValueInUsd":"6259.8","indian_port":"Madras Air","hs_no":"29335990","bill_no":"8199954","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN","supplierAddress":"STRADA RIVOLTANA KM 6\/7 RODANO MI 20053 SDNF ITALY","customerAddress":"HETERO CORPORATE, NO. 7-2-A2,"}]
11-Apr-2022
28-Oct-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

INTERMEDIATE SUPPLIERS

read-more
read-more

01

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 1799799-87-3

End Use API : Zanubrutinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

02

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 84358-13-4

End Use API : Zanubrutinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

03

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 330792-70-6

End Use API : Zanubrutinib

About The Company : Integrin Life Sciences Pvt. Ltd. is one of the growing pharmaceutical API, advanced chemical intermediates manufacturing companies in India. Our Plant is Locate...

blank

04

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 1799799-87-3

End Use API : Zanubrutinib

About The Company : Integrin Life Sciences Pvt. Ltd. is one of the growing pharmaceutical API, advanced chemical intermediates manufacturing companies in India. Our Plant is Locate...

blank

05

Royal Pharma

India
COMPAMED
Not Confirmed
arrow

Royal Pharma

India
COMPAMED
Not Confirmed
arrow

CAS Number : 330792-70-6

End Use API : Zanubrutinib

About The Company : Royal pharma was started in 2007 – it’s a small scale Advanced Intermediates Manufacturing company. Facilities are in accordance to GMP standards. Currently...

blank

06

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 206989-61-9

End Use API : Zanubrutinib

About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...

blank

07

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 1799799-87-3

End Use API : Zanubrutinib

About The Company : VIDGAS is dedicated to delivering the highest quality SFC and HPLC purification and isolation solutions to clients across the pharmaceutical, biopharmaceutical,...

blank

08

COMPAMED
Not Confirmed
arrow
COMPAMED
Not Confirmed
arrow

CAS Number : 2190506-55-7

End Use API : Zanubrutinib

About The Company : VIDGAS is dedicated to delivering the highest quality SFC and HPLC purification and isolation solutions to clients across the pharmaceutical, biopharmaceutical,...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

ZANUBRUTINIB

Brand Name : BRUKINSA

Dosage Form : CAPSULE;ORAL

Dosage Strength : 80MG

Approval Date : 2019-11-14

Application Number : 213217

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

02

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

ZANUBRUTINIB

Brand Name : BRUKINSA

Dosage Form : TABLET;ORAL

Dosage Strength : 160MG

Approval Date : 2025-06-10

Application Number : 218785

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

03

The Pharmacy Technology
Not Confirmed
arrow
arrow
The Pharmacy Technology
Not Confirmed

ZANUBRUTINIB

Brand Name : BRUKINSA

Dosage Form : CAPSULE; ORAL

Dosage Strength : 80MG

Approval Date :

Application Number : 218785

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1651179-04-2 / Zanubrutinib API manufacturers, exporters & distributors?

Zanubrutinib manufacturers, exporters & distributors 1

68

PharmaCompass offers a list of Zanubrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zanubrutinib manufacturer or Zanubrutinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zanubrutinib manufacturer or Zanubrutinib supplier.

PharmaCompass also assists you with knowing the Zanubrutinib API Price utilized in the formulation of products. Zanubrutinib API Price is not always fixed or binding as the Zanubrutinib Price is obtained through a variety of data sources. The Zanubrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Zanubrutinib

Synonyms

1691249-45-2, Brukinsa, Bgb-3111, Zanubrutinib [inn], Zanubrutinib [usan], Ag9mhg098z

Cas Number

1651179-04-2

Unique Ingredient Identifier (UNII)

AG9MHG098Z

About Zanubrutinib

Zanubrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.

Zanubrutinib Manufacturers

A Zanubrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zanubrutinib, including repackagers and relabelers. The FDA regulates Zanubrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zanubrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Zanubrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Zanubrutinib Suppliers

A Zanubrutinib supplier is an individual or a company that provides Zanubrutinib active pharmaceutical ingredient (API) or Zanubrutinib finished formulations upon request. The Zanubrutinib suppliers may include Zanubrutinib API manufacturers, exporters, distributors and traders.

click here to find a list of Zanubrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Zanubrutinib USDMF

A Zanubrutinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Zanubrutinib active pharmaceutical ingredient (API) in detail. Different forms of Zanubrutinib DMFs exist exist since differing nations have different regulations, such as Zanubrutinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Zanubrutinib DMF submitted to regulatory agencies in the US is known as a USDMF. Zanubrutinib USDMF includes data on Zanubrutinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Zanubrutinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Zanubrutinib suppliers with USDMF on PharmaCompass.

Zanubrutinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Zanubrutinib Drug Master File in Korea (Zanubrutinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Zanubrutinib. The MFDS reviews the Zanubrutinib KDMF as part of the drug registration process and uses the information provided in the Zanubrutinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Zanubrutinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Zanubrutinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Zanubrutinib suppliers with KDMF on PharmaCompass.

Zanubrutinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zanubrutinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Zanubrutinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Zanubrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Zanubrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zanubrutinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Zanubrutinib suppliers with NDC on PharmaCompass.

Zanubrutinib GMP

Zanubrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Zanubrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zanubrutinib GMP manufacturer or Zanubrutinib GMP API supplier for your needs.

Zanubrutinib CoA

A Zanubrutinib CoA (Certificate of Analysis) is a formal document that attests to Zanubrutinib's compliance with Zanubrutinib specifications and serves as a tool for batch-level quality control.

Zanubrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Zanubrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Zanubrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Zanubrutinib EP), Zanubrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zanubrutinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty